QIAGEN N.V.  / Key word(s): Quarter Results

29.10.2012 21:19

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Venlo, The Netherlands, October 29, 2012 - QIAGEN N.V. (NASDAQ: QGEN;
Frankfurt Prime Standard: QIA) announces today that it has decided to
postpone the issuance of its report for third quarter and first nine months
of 2012 due to the severe weather conditions in the United States and
closing of U.S. stock exchanges due to Hurricane Sandy.

The report is now planned to be issued on Sunday, November 4, at 18:00
Central European Time / 17:00 London time / 12:00 Eastern Standard Time.
(Previously scheduled for Monday, October 29.)

The conference call is now planned to be held on Monday, November 5, at
15:30 Central European Time / 14:30 London time / 9:30 Eastern Standard
Time. (Previously scheduled for Tuesday, October 30.) The corresponding
presentation slides will be available for download shortly before the event
at www.qiagen.com/goto/ConferenceCall, and a webcast will be available at
this website. A replay will also be made available on this website.

QIAGEN strives to allow equal access to information made public by the
Company, and that investors also have access to trading on NASDAQ and the
Frankfurt Stock Exchange, where its global shares are listed.  Based on a
number of factors - which include severe weather conditions in the
Northeastern region of the U.S.; the closing of NASDAQ on Tuesday, October
30; and a holiday on Thursday, November 1, in many areas of Europe - QIAGEN
feels that postponing the release of this information until Sunday,
November 4, is in the best interest of shareholders.
About QIAGEN
QIAGEN N.V., a Netherlands holding company, is the leading global provider
of Sample & Assay Technologies that are used to transform biological
materials into valuable molecular information. Sample technologies are used
to isolate and process DNA, RNA and proteins from biological samples such
as blood or tissue. Assay technologies are then used to make these isolated
biomolecules visible and ready for interpretation. QIAGEN markets more than
500 products around the world, selling both consumable kits and automation
systems to customers through four customer classes: Molecular Diagnostics
(human healthcare), Applied Testing (forensics, veterinary testing and food
safety), Pharma (pharmaceutical and biotechnology companies) and Academia
(life sciences research). As of September 30, 2012, QIAGEN employed
approximately 4,000 people in over 35 locations worldwide. Further
information can be found at http://www.qiagen.com/.

###
Contacts:
Corporate Communications
  
Investor Relations   
John Gilardi 
+49 2103 29 11711
+1 240 686 2222
e-mail: ir@qiagen.com

Public Relations
Dr. Thomas Theuringer 
+49 2103 29 11826
e-mail: pr@qiagen.com 


29.10.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      QIAGEN N.V.
              Spoorstraat 50
              5911 KJ Venlo
              Netherlands
Phone:        +31 77320 840-0
Fax:          +31 77320 840-9
E-mail:       qiagen@qiagen.com
Internet:     www.qiagen.com
ISIN:         NL0000240000
WKN:          901626
Indices:      TecDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart;
              Terminbörse EUREX
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------